Metabolomic biomarkers may support clinicians in future differential diagnosis of atopic dermatitis in order to achieve early diagnosis of DOCK8 deficiency [41], but currently, the diagnosis demands experienced clinicians and intracellular flow cytometry for DOCK8, most successfully detected in B-cells, which show minimal reversion [8], and confirmation by Sanger and/or exome sequencing. This evidence concerns the gene DOCK8 and combined immunodeficiency due to DOCK8 deficiency.